1. At a Glance
Pfizer Ltd (yes, the Indian arm of that Pfizer) just reported its Q2FY26 results and — like a patient avoiding the gym — the company’s health metrics are decent but not inspiring. Revenue stood at ₹642 crore, up 9% YoY, while PAT rose 19% YoY to ₹189 crore. The stock closed at ₹5,074, valuing the company at a market cap of ₹23,212 crore, trading at a P/E of 32.8x — because, apparently, nostalgia for “trustworthy MNC pharma” still commands a premium.
Return on equity sits at 16.4%, with ROCE of 21.6%, and a debt-to-equity ratio of just 0.01 — meaning Pfizer’s debt levels are as negligible as your faith in Indian pharma after seeing NLEM updates. But wait — the sales growth for 5 years is just 1.18%, a speed slower than Indian bureaucracy on a Monday morning.
As the Bhagavad Gita reminds us: “You have the right to perform your prescribed duty, but not to the fruits of your actions.” Pfizer’s duty seems to be maintaining global brand prestige — while the fruits (or capsules) are smaller every quarter.
The company has been recalling products, divesting land, and battling ceiling price revisions — yet still manages to throw a dividend yield of 0.69%, because who doesn’t love small doses of comfort in tough times?
2. Introduction
Pfizer India is that rich cousin from the U.S. who shows up occasionally, flexes its international degree, then leaves before paying the dinner bill. As a subsidiary of Pfizer Inc., one of the world’s biggest pharma giants, the Indian arm enjoys a halo of respectability — the kind that makes retail investors whisper, “Yeh toh safe hai boss.”
Except, it hasn’t really grown much. Between FY22 and FY24, Pfizer’s total revenue actually fell by 16%, courtesy of product recalls (Magnex, Zosyn, and Magnamycin — no, these aren’t Marvel villains, just antibiotics gone rogue) and NLEM 2022 price revisions, which basically told pharma companies, “No more supernormal profits from essential drugs, beta.”
Still, Pfizer’s operating margins of 34% are envy-worthy. While local peers like Zydus and Lupin fight over market share and compliance headaches, Pfizer lounges in Goa (literally — that’s where its factory is) producing 3.6 billion tablets annually and partnering with 18 contract manufacturers for another 1.9 billion.
If you’re wondering, that’s about 6 billion tiny soldiers a year — yet revenue barely moves. It’s like hosting the Kumbh Mela every year but making the same profit as a chai stall.
3. Business Model – WTF Do They Even Do?
Pfizer India is in the manufacture, marketing, and export of pharmaceutical products — or, in simpler terms, they sell pills, syrups, and injections with more difficult names than your Wi-Fi password.
Their product portfolio reads like a who’s who of Indian households — Gelusil for acidity, Corex DX for cough, Mucaine for heartburn, Ativan for anxiety (which, ironically, investors might need), and Prevenar 13, the famous pneumococcal vaccine that makes Pfizer
